Gritstone Bio Other Non-Current Liabilities 2017-2024 | GRTSQ
Gritstone Bio other non-current liabilities from 2017 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Gritstone Bio Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$1 |
| 2022 |
$0 |
| 2021 |
$ |
| 2020 |
$0 |
| 2019 |
$ |
| 2018 |
$0 |
| 2017 |
$0 |
| 2016 |
$0 |
Gritstone Bio Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$1 |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$1 |
| 2023-06-30 |
$0 |
| 2023-03-31 |
$0 |
| 2022-12-31 |
$0 |
| 2022-09-30 |
$0 |
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
$0 |
| 2021-06-30 |
$0 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$1 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
$0 |
| 2018-12-31 |
$0 |
| 2018-09-30 |
$0 |
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2016-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
